Wedbush Downgrades Ikena Oncology to Neutral, Lowers Price Target to $2

Benzinga · 05/29 12:12
Wedbush analyst David Nierengarten downgrades Ikena Oncology (NASDAQ:IKNA) from Outperform to Neutral and lowers the price target from $8 to $2.